Share Agreements in the Biotechnology Industry
298 Contracts & Agreements
- 2seventy bio, Inc. (2 contracts)
- ACHIEVE LIFE SCIENCES, INC. (1)
- Adaptimmune Therapeutics PLC (4)
- Adhera Therapeutics, Inc. (1)
- ADMA BIOLOGICS, INC. (1)
- ADURO BIOTECH, INC. (1)
- Allogene Therapeutics, Inc. (2)
- ALNYLAM PHARMACEUTICALS, INC. (1)
- AMARIN CORP PLC (1)
- Amgen Inc. (4)
- AmpliPhi Biosciences Corp (1)
- Anchiano Therapeutics Ltd. (1)
- Aptose Biosciences Inc. (2)
- Arbutus Biopharma Corp (2)
- Arsanis, Inc. (1)
- ARYA Sciences Acquisition Corp II (1)
- Athenex, Inc. (2)
- Avid Bioservices, Inc. (2)
- Axovant Sciences Ltd. (1)
- BeiGene, Ltd. (16)
- Benitec Biopharma Inc. (1)
- BICYCLE THERAPEUTICS Ltd (7)
- Big Cypress Acquisition Corp. (1)
- BioAtla, Inc. (1)
- Biohaven Pharmaceutical Holding Co Ltd. (3)
- BIOMARIN PHARMACEUTICAL INC (1)
- BIOTIME INC (6)
- bluebird bio, Inc. (1)
- BRAINSTORM CELL THERAPEUTICS INC. (5)
- CANCER GENETICS, INC (4)
- CAPRICOR THERAPEUTICS, INC. (3)
- CareDx, Inc. (9)
- CATALYST BIOSCIENCES, INC. (1)
- Cellectar Biosciences, Inc. (1)
- Cellular Biomedicine Group, Inc. (2)
- Centessa Pharmaceuticals Ltd (2)
- Chardan Healthcare Acquisition Corp. (1)
- CLEVELAND BIOLABS INC (1)
- COMPASS Pathways plc (1)
- Consonance-HFW Acquisition Corp. (1)
- Constellation Alpha Capital Corp. (1)
- CONTRAFECT Corp (1)
- Cybrdi, Inc. (2)
- CytomX Therapeutics, Inc. (1)
- CYTORI THERAPEUTICS, INC. (1)
- DBV Technologies S.A. (3)
- Denali Therapeutics Inc. (1)
- DiaMedica Therapeutics Inc. (1)
- Dicerna Pharmaceuticals Inc (3)
- Diffusion Pharmaceuticals Inc. (1)
- Dynamics Special Purpose Corp. (2)
- Edge Therapeutics, Inc. (1)
- Emerald Bioscience, Inc. (2)
- Enochian Biosciences Inc (1)
- EXICURE, INC. (1)
- Fibrocell Science, Inc. (1)
- Fusion Pharmaceuticals Inc. (3)
- GALECTIN THERAPEUTICS INC (1)
- Generation Bio Co. (1)
- GeoVax Labs, Inc. (1)
- Gilead Sciences (1)
- Health Sciences Acquisitions Corp (1)
- iBio, Inc. (3)
- IDERA PHARMACEUTICALS, INC. (4)
- Immix Biopharma, Inc. (1)
- IMMUCELL CORP (1)
- IMMUNE PHARMACEUTICALS INC (1)
- Immuneering Corp (1)
- IMMUNOGEN INC (1)
- Incyte (1)
- InMed Pharmaceuticals Inc. (2)
- Innovation Pharmaceuticals Inc. (1)
- Instil Bio, Inc. (1)
- INTERCEPT PHARMACEUTICALS, INC. (2)
- INTREXON CORP (1)
- Invitae Corp (1)
- Isoray, Inc. (2)
- Kiniksa Pharmaceuticals, Ltd. (8)
- LEXICON PHARMACEUTICALS, INC. (1)
- LianBio (5)
- MARIZYME INC (2)
- MEDICINOVA INC (1)
- MEI Pharma, Inc. (1)
- MeiraGTx Holdings plc (2)
- NEUROTROPE BIOSCIENCE, INC. (1)
- NOVAVAX INC (1)
- Novus Therapeutics, Inc. (2)
- Opko Health, Inc. (4)
- Organicell Regenerative Medicine, Inc. (1)
- PALATIN TECHNOLOGIES INC (1)
- PDL BIOPHARMA, INC. (1)
- Petra Acquisition Inc. (1)
- PharmaCyte Biotech, Inc. (1)
- PLURISTEM THERAPEUTICS INC (2)
- Prothena Corp plc (1)
- Rallybio Corp (4)
- Repare Therapeutics Inc. (2)
- Rezolute, Inc. (4)
- RHYTHM PHARMACEUTICALS, INC. (1)
- RITTER PHARMACEUTICALS INC (2)
- ROCKET PHARMACEUTICALS, INC. (1)
- SANGAMO THERAPEUTICS, INC (2)
- Sesen Bio, Inc. (1)
- Social Capital Suvretta Holdings Corp. III (2)
- Sorrento Therapeutics, Inc. (2)
- Spectrum Pharmaceuticals, Inc. (26)
- Spero Therapeutics, Inc. (1)
- SPHERIX INC (1)
- Spinning Eagle Acquisition Corp. (2)
- Stellar Biotechnologies, Inc. (1)
- Sunshine Biopharma, Inc (2)
- Synthetic Biologics, Inc. (3)
- TYME TECHNOLOGIES, INC. (1)
- uniQure N.V. (1)
- United Therapeutics Corp (11)
- Vaccitech plc (1)
- Vaxxinity, Inc. (1)
- Xenetic Biosciences, Inc. (7)
- Xenon Pharmaceuticals Inc. (5)
- XOMA Corp (20)
- Zai Lab Ltd (2)
- ZIOPHARM ONCOLOGY INC (2)
- Zymeworks Inc. (1)
- Amendment No. 4 to Brainstorm Cell Therapeutics Inc. 2014 Global Share Option Plan (BRAINSTORM CELL THERAPEUTICS INC., Filed With SEC on September 16, 2024)
- Form Restricted Share Unit Award Agreement (Zai Lab Ltd, Filed With SEC on August 6, 2024)
- Share Purchase Agreement, dated June 12, 2024, by and among Ever After and the Investors (PLURISTEM THERAPEUTICS INC, Filed With SEC on June 18, 2024)
- Form of Share Purchase Agreement by and between the Company and certain investors, dated June 11, 2024 (Social Capital Suvretta Holdings Corp. III, Filed With SEC on June 13, 2024)
- Fourth Amended and Restated 2018 Employee Share Purchase Plan (BeiGene, Ltd., Filed With SEC on June 5, 2024)
- Share Purchase Agreement, by and between Sopharma AD and Achieve Life Sciences, Inc., dated May 14, 2015 (ACHIEVE LIFE SCIENCES, INC., Filed With SEC on March 28, 2024)
- Seller Economic Share Agreement by and between Senti Biosciences, Inc., GeneGab, LLC, and Valere Bio, Inc., dated August 7, 2023 (Dynamics Special Purpose Corp., Filed With SEC on November 14, 2023)
- Share Purchase Agreement, dated October 31, 2023, by and between Synaptogenix, Inc. and Cannasoul Analytics Ltd (NEUROTROPE BIOSCIENCE, INC., Filed With SEC on November 6, 2023)
- Second Amendment to Amended and Restated Co-Development, Co-Promote and Profit Share Agreement, between 2seventy bio, Inc., Celgene Corporation and Celgene Investment Company LLC,... (2seventy bio, Inc., Filed With SEC on August 14, 2023)
- Adaptimmune Therapeutics plc 2016 Employee Share Option Scheme (Adaptimmune Therapeutics PLC, Filed With SEC on June 29, 2023)
- Adaptimmune Therapeutics plc 2015 Share Option Scheme (Adaptimmune Therapeutics PLC, Filed With SEC on June 29, 2023)
- Common Share Purchase Agreement, dated as of May 25, 2023, by and between the Company and Keystone Capital Partners, LLC (Aptose Biosciences Inc., Filed With SEC on May 26, 2023)
- Share Purchase Agreement, dated March 23, 2023, by and between the registrant and ModernaTX, Inc (Generation Bio Co., Filed With SEC on May 10, 2023)
- Form of Letter Agreement with certain holders of Common Share Purchase Warrants of Marizyme, Inc. dated August 4, 2020 (MARIZYME INC, Filed With SEC on April 20, 2023)
- Share Purchase Agreement, dated March 13, 2023, by and between Vyant Bio, Inc. and Sabine Brandt as trustee for the Brandt Family Trust (CANCER GENETICS, INC, Filed With SEC on March 15, 2023)
- 2022 Free Share Plan (English translation) (DBV Technologies S.A., Filed With SEC on March 2, 2023)
- Share Purchase Agreement, by and between Rhythm Pharmaceuticals Netherlands B.V. and Xinvento B.V., dated February 27, 2023 (RHYTHM PHARMACEUTICALS, INC., Filed With SEC on March 1, 2023)
- Amendment No. 3 to Share Purchase Agreement, dated January 30, 2023, by and between the Registrant and Amgen Inc (BeiGene, Ltd., Filed With SEC on February 27, 2023)
- Amendment No. 3 to Share Purchase Agreement, dated January 30, 2023, by and among BeiGene, Ltd. and Amgen Inc (Amgen Inc., Filed With SEC on January 31, 2023)
- Amendment No. 1 to the Share Purchase Agreement (Emerald Bioscience, Inc., Filed With SEC on January 27, 2023)
- Form of Share Purchase Agreement (Immix Biopharma, Inc., Filed With SEC on January 18, 2023)
- Share Purchase Agreement, dated December 30, 2022, by and between vivoPharm Pty, Ltd. and Sabine Brandt as trustee for the Brandt Family Trust (CANCER GENETICS, INC, Filed With SEC on January 5, 2023)
- Share Transfer Agreement by and between PDS Biotechnology Corporation and Merck KGaA, Darmstadt, Germany (Edge Therapeutics, Inc., Filed With SEC on January 3, 2023)
- Share Purchase Agreement, dated November 8, 2022, by and between Emerald Health Therapeutics, Inc., 14428773 Canada Inc., Verdelite Sciences, Inc., Verdelite Property Holdings,... (Emerald Bioscience, Inc., Filed With SEC on November 14, 2022)
- Form of Restricted Share Unit Award Agreement (Zai Lab Ltd, Filed With SEC on November 9, 2022)
- Share Purchase Agreement between Sunshine Biopharma, Inc., Malek Chamoun and Nora Pharma Inc (Sunshine Biopharma, Inc, Filed With SEC on October 20, 2022)
- First Amendment to the Share Purchase Agreement, dated May 11, 2022, by and among the Registrant, Overland Pharmaceuticals (CY) Inc. and Allogene Overland Biopharm (CY) Limited (Allogene Therapeutics, Inc., Filed With SEC on August 9, 2022)
- Form of Inducement Award Non-Qualified Share Option Agreement (COMPASS Pathways plc, Filed With SEC on August 4, 2022)
- Amendment to Share Purchase Agreement, dated July 1, 2022, between ICPT Inc. and Mercury Pharma (INTERCEPT PHARMACEUTICALS, INC., Filed With SEC on August 3, 2022)
- Share Purchase Agreement, dated May 5, 2022, between Intercept Pharmaceuticals, Inc. (ICPT Inc.) as seller and Mercury Pharma Group Limited (Mercury Pharma) as purchaser (INTERCEPT PHARMACEUTICALS, INC., Filed With SEC on August 3, 2022)
- Share Purchase and Transfer Agreement, dated June 16, 2017, by and among registrant, HBL-Hadasit Bio-Holdings Ltd. and Cell Cure Neurosciences Ltd (BIOTIME INC, Filed With SEC on June 17, 2022)
- Series A Preferred Share Purchase Agreement, dated June 9, 2022, by and among Squalus Med Ltd. and Innovation Pharmaceuticals Inc (Innovation Pharmaceuticals Inc., Filed With SEC on June 15, 2022)
- Share Purchase Agreement between the Company and Alpha Capital Anstalt dated April 29, 2022 (RITTER PHARMACEUTICALS INC, Filed With SEC on May 13, 2022)
- Series B Preferred Share Purchase Agreement between the Company and NanoSynex Ltd. dated April 29, 2022 (RITTER PHARMACEUTICALS INC, Filed With SEC on May 13, 2022)
- Share Purchase Agreement, dated January 5, 2022, by and among Tnuva Food-Tech Incubator (2019), Limited Partnership, Plurinuva Ltd. and Pluristem Ltd (PLURISTEM THERAPEUTICS INC, Filed With SEC on May 9, 2022)
- Form of Non-Performance Based Share Option Agreement (Employees) (LianBio, Filed With SEC on March 31, 2022)
- Form of Non-Performance Based Restricted Share Unit Agreement (LianBio, Filed With SEC on March 31, 2022)
- Description of Share Capital (Anchiano Therapeutics Ltd., Filed With SEC on March 30, 2022)
- Form of Share Purchase Agreement (2seventy bio, Inc., Filed With SEC on March 16, 2022)
- Amendment, dated March 9, 2022, to the Share Purchase Agreement, by and among Synthetic Biologics, Inc., VCN Biosciences, S.L. and the shareholders of VCN Biosciences, S.L., dated... (Synthetic Biologics, Inc., Filed With SEC on March 11, 2022)
